Amlitelimab matching placebo comprised of the same excipients as the Test product without the active substance clinical trials

A Phase 2, randomized, double-blind, placebo-controlled, parallel group, proof-of-concept study assessing the efficacy and safety of amlitelimab in adult participants with moderate to severe hidradenitis suppurativa.

This study is testing a new medicine, amlitelimab, for adults with moderate to severe hidradenitis suppurativa (HS). Researchers want to see if it helps improve HS symptoms and is safe, compared to a dummy drug, over 16 weeks.